Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?

  • Alberto Garcia-Zamalloa Internal Medicine Service, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain; Pleural-Respiratory Research Unit, Biodonostia Health Research Institute, Gipuzkoa, Spain
  • Maria Begoña Basauri Biochemistry Laboratory, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain
  • Maria Goretti Urcelay Biochemistry Laboratory, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain
  • Adriana Sanz Haematology Service, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain
DOI: https://doi.org/10.12890/2023_003921

Keywords

Dasatinib, chylothorax, pleural effusion

Abstract

Dasatinib is a tyrosine kinase inhibitor used for treatment of some specific types of leukaemia. The development of pleural effusion is a known adverse effect of dasatinib and chylothorax is exceptional. No case has been reported beyond 5 years of treatment and extensive search for an alternative diagnosis is currently suggested in such scenario. The underlying mechanism is not currently clear. We describe a woman on dasatinib treatment for more than 10 years who developed chylothorax. Drug withdrawal resolved the chylous pleural effusion. We were able to find 14 additional cases of dasatinib-related chylothorax reported up until now.

Author Biographies

Maria Begoña Basauri ,
Biochemistry Laboratory, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain

Osakidetza- Basque Health Service

Mendaro Hospital

Biochemistry Laboratory.

Staff. 

Maria Goretti Urcelay ,
Biochemistry Laboratory, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain

Osakidetza-Basque Health Service

Mendaro Hospital

Biochemistry Laboratory

Director

Adriana Sanz ,
Haematology Service, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain

Osakidetza-Basque Health Service

Mendaro Hospital

Hematology Service

Staff

VIEW THE ENTIRE ARTICLE

References

  • Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123–1129.
  • Quintás-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
  • Kelly RL, Bae JY, D’Annunzio S, Montanari F. Diagnostic pitfalls of chylothorax after dasatinib treatment of chronic myeloid leukemia. Am J Case Rep 2022;23: e938319.
  • Al-Abcha A, Iftikhar MH, Abu Rous F, Laird-Fick H. Chylothorax: complication attributed to dasatinib use. BMJ Case Rep 2019;12:e231653.
  • Paul T, Ellahie AY, Almohtasib YS, Sinha U, El Omri H. Dasatinib-induced chylothorax: an unusual presentation of a common adverse event—a case report with literature review. EJHaem 2021;2:545–550.
  • Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814–818.
  • Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, et al. Dasatinib increases endotelial permeability leading to pleural effusion. Eur Respir J 2018;51: 1701096.
  • Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333–2340.
  • Ferreiro L, San-José E, Suárez-Antelo J, Valdés L. Dasatinib-induced pleural effusion: chylothorax, an option to consider. Ann Thorac Med 2016;11:289–293.
  • Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377–386.
  • De Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008;141:745–747.
  • Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Douglas Smith B. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk 2017;17:78–82.
  • Koylu B, Tekin F, Aktas BY, Kilickap S, Koksal D. Pazopanib-induced chylothorax in a patient with renal cell carcinoma. Anticancer Drugs 2022;33:e555–e57.

    • Published: 2023-06-07

    Issue: 2023: Vol 10 No 7 (view)

    Section: Articles

    How to cite:
    1.
    Garcia-Zamalloa A, Basauri MB, Urcelay MG, Sanz A. Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?. EJCRIM 2023;10 doi:10.12890/2023_003921.